Curing blindness through regenerative cell therapies. We replace what is lost.

StemSight develops off-the-shelf cell therapies to address unmet medical needs in corneal blindness. ​

We are the pioneers of combining iPS-derived cells with functional biomaterials. Our primary goal is to accelerate tissue regeneration, enhance the safety of cell therapies, and simplify cell delivery.

<p><span>The most innovative startup in health and life sciences in Europe at BioFit, 2020</span></p>

The most innovative startup in health and life sciences in Europe at BioFit, 2020

Award winner at TechTour’s flagship event, Europe’s Most Innovative Companies, 2022
Award winner at TechTour’s flagship event, Europe’s Most Innovative Companies, 2022
Finalist at EIT Health Catapult Biotech pitching competition, 2022-2023
Finalist at EIT Health Catapult Biotech pitching competition, 2022-2023

About us

The founding team of StemSight is comprised of top scientists in regenerative medicine and tissue engineering for eye applications. The scientific excellence is complemented by our distinguished board of accomplished industry leaders and advisors with extensive global business acumen.
READ MORE

Latest News

2026-11-02 00:00:00

StemSight Wins Startup World Cup Finland and Heads to Global Finals in San Francisco!

We are thrilled to announce that StemSight has won the Finnish regional finals of the Startup World Cup 2026, held in Tampere on October 15, and will represent Finland at the global finals in San Francisco on November 4–6!

Organized by Pegasus Tech Ventures, the Startup World Cup is one of the world's largest startup competitions, bringing together innovative companies from across the globe.

In San Francisco, StemSight will compete in the semi-finals against more than 200 regional winners from around the world. The top 10 startups will advance to the Grand Finale, where they will pitch for the $1 million investment grand prize.

2026-10-09 00:00:00

StemSight joins Endless Frontier Labs 2026-27 cohort

StemSight has been selected to join the Endless Frontier Labs’ 2026-27 cohort alongside 99 other ground-breaking companies! We look forward to working with EFL mentors, NYU Stern MBA students, and the rest of the companies selected for the Life Sciences track over the next 9 months.

 

2026-08-17 00:00:00

Life Science Leader article

In a new Life Science Leader guest column, StemSight CEO Laura Koivusalo discusses how the biotech industry's traditional risk-sharing model is evolving. The article highlights the growing need for stronger collaboration ecosystems to advance the next generation of regenerative medicines.

2026-06-16 00:00:00

StemSight granted patent in Singapore

StemSight has been granted a patent in Singapore, and received a notice of patent allowance in Canada and Japan. With the first patent now granted for the novel product, StemSight is entering an important growth phase as we prepare for Series A financing and future clinical development. Read the full press release here.

More News

Want to know more?

Interested to join our next investment round? Want to hear about our latest developments? Just thought of someone we absolutely need to meet?

Send us a message!

CONTACT US

Subscribe to our newsletter

Subscribe now

Supported by:

Co-funded by: